Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
THE
PERFECT BLEND
The next frontier in cancer immunotherapy lies in
combining it with other treatments. Scientists are
trying to get the mix just right.
BY HEIDI LEDFORD
LYING IN WAIT
1 6 2 | NAT U R E | VO L 5 3 2 | 1 4 A P R I L 2 0 1 6
MARGARET OECHSLI
Some cancer drugs (pictured here, dried adriamycin viewed under a microscope) might work better when paired with immunotherapies.
DESPERATELY
SEEKING SURVIVAL
Survival
Targeted therapy
Standard therapy
Immunotherapy
Standard therapy
Survival
1
2
Years after diagnosis
MIXING IT UP
COMBINATORIAL EXPLOSION
Projected
Ipilimumab, the first approved checkpoint inhibitor, has been tested in dozens of clinical trials since 2001.
And like many other drugs in its class, it is increasingly being tested in combination with other therapies.
60
US regulators approve
Combination therapy
ipilimumab for treatment
50
Single-drug therapy
of advanced melanoma.
40
30
20
10
0
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
1 6 4 | NAT U R E | VO L 5 3 2 | 1 4 A P R I L 2 0 1 6
DATA FRENZY
SOURCE: CLINICALTRIALS.GOV
NEWS FEATURE